BioCardia

BioCardia EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of BioCardia (BCDA) as of Nov 21, 2026 is 184.11. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 25.81 — a change of 613.39% (higher).

EV/Revenue

184.11

YoY

613.39%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of BioCardia is 2024 184.11 . EV/Revenue (Enterprise Value to Revenue) of BioCardia was 2023 25.81 . It decreases by 613.39% higher compared to the previous year.

The BioCardia EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2017
-0.97 USD
Jan 1, 2018
10.78 USD
Jan 1, 2019
10.78 USD
Jan 1, 2020
-59.96 USD
Jan 1, 2021
1.08 USD
Jan 1, 2022
4.71 USD
Jan 1, 2023
25.81 USD
Jan 1, 2024
184.11 USD
The BioCardia EV/Revenue history
YEAREV/RevenueYoY
184.11+613.39%
25.81+448.07%
4.71+336.69%
1.08-101.80%
-59.96-656.11%
10.78-0.02%
10.78-1,207.42%
-0.97-93.61%
-15.24-300.40%
7.60-46.69%
14.26—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCardia Stock analysis

What does BioCardia do? BioCardia, Inc. generates revenue through its clinical-stage regenerative medicine portfolio, primarily focused on CardiAMP and CardiALLO cell therapies. The CardiAMP Cell Therapy System is in Phase III trials for ischemic systolic heart failure, targeting healthcare providers and clinical trial sponsors seeking advanced treatments for heart failure patients. CardiALLO, an allogeneic off-the-shelf mesenchymal stem cell product, is developed for broader therapeutic applications, appealing to hospitals and research institutions requiring ready-to-use regenerative solutions. The company also monetizes the Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products, which serve as complementary tools for medical professionals during therapeutic procedures. CardiAMP and CardiALLO are positioned as innovative therapeutic candidates targeting heart failure and regenerative medicine segments, with CardiAMP advancing toward potential commercialization in late-stage trials. The Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products cater to interventional cardiology and surgical markets, providing specialized equipment for clinicians. BioCardia's revenue streams are derived from partnerships with clinical trial sponsors and direct sales of medical devices to healthcare facilities, focusing on cardiovascular and regenerative medicine applications. The company's business model relies on developing and commercializing cell therapies and medical devices, with CardiAMP leading the portfolio in late-stage development. CardiALLO serves as a complementary allogeneic product, while the Helix and Morph products support procedural needs in cardiology. Revenue is anticipated from future commercialization of CardiAMP post-trial success and from ongoing sales of the Helix and Morph systems to medical institutions. BioCardia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioCardia stock

EV/Revenue (Enterprise Value to Revenue) of BioCardia is 184.11 in 2024.

EV/Revenue (Enterprise Value to Revenue) of BioCardia changed from 25.81 to 184.11, representing a 613.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) BioCardia since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s BioCardia with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioCardia

All Key Metrics — BioCardia